Akebia therapeutics reports inducement grants under nasdaq listing rule 5635(c)(4)

Cambridge, mass., feb. 04, 2025 (globe newswire) -- akebia therapeutics ® , inc. (nasdaq: akba), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted seven newly-hired employees options to purchase an aggregate of 130,763 shares of akebia's common stock on january 31, 2025. the options were granted as an inducement material to teach employee entering into employment with akebia. the options were granted in accordance with nasdaq listing rule 5635(c)(4).
NDAQ Ratings Summary
NDAQ Quant Ranking